英克雷丁疗法:一种新工具来对抗抗精神病使用的代谢后果
Amre A Elmaoued1, Raechel T White2,3
1University of New Mexico College of Pharmacy, Albuquerque, New Mexico.
The primary care companion for CNS disorders
|September 12, 2025
概括
在服用抗精神病药物的患者中,因克雷丁疗法对管理体重增加和代谢问题有前途. 进一步的研究证实了它们在这个人群中的潜在安全性和有效性.
科学领域:
- 精神病学和内分泌学 精神病学和内分泌学
- 代谢综合征研究 代谢综合征研究
- 药理学 药理学是指药理学的学科.
背景情况:
- 抗精神病药物经常导致代谢障碍,如体重增加,脂质不良和葡萄糖不耐受.
- 胰岛素疗法为控制这些不良影响提供了潜在的解决方案.
- 有限的临床试验数据存在于精神病患者群体内因克雷丁的使用.
研究的目的:
- 审查与抗精神病药物使用相关的代谢并发症的因克雷丁疗法的疗效和安全性.
- 为精神病医疗提供者开发使用隐形剂的处方指南.
主要方法:
- 相关文献的叙述性审查,包括包装插件,临床指南和心脏代谢试验.
- 在精神病患者中开发一种处方指南和用于因克雷丁治疗的算法.
主要成果:
- 初步数据表明,在患有精神疾病的患者中,可以有效地使用因克雷丁疗法.
- 创建了一个全面的处方指南,详细介绍了药物选择,剂量,禁忌和临床考虑.
- 该指南协助提供者管理精神病的并发症,并与英克雷丁治疗.
结论:
- 在一般人群中,因克雷丁疗法是已建立的糖尿病和体重管理治疗方法.
- 这些药物在适当监测下,在精神病患者的肥胖和糖尿病治疗中显示出潜在的有效性和安全性.
- 建议对使用英克雷丁治疗的精神病患者进行进一步的调查和仔细监测.
相关概念视频
01:24Glucagon-like Receptor Agonists
854
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
854
01:23Dipeptidyl Peptidase 4 Inhibitors
598
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
598
01:28Drug Therapy
246
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
246
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
588
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
588
01:26Psychosis: Goals of Pharmacotherapy
476
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
476
01:23Antidepressant Drugs: MAOIs and Other Agents
831
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
831